DNA Diagnostics Market Overview
DNA Diagnostics Market is Expected to Reach $19 Billion, Globally, by 2020
In terms of geography, the market is segmented into North America, Asia Pacific, Europe and LAMEA. North America holds the dominant share in the market due to the increased adoption of the DNA diagnostics technology and the high prevalence of chronic and infectious diseases. Global DNA diagnostics market is expected to garner $19 billion by 2020, registering a CAGR of 9.8% during the forecast period 2014-2020.
Download Sample Report : https://www.alliedmarketresearch.com/request-sample/298
The latest figures suggest that approximately 8.2 million people are living with cancer and 39 million with HIV. These numbers are set to increase consistently; however, advanced automated DNA diagnostics technologies such as next generation sequencing could play a crucial role in diagnosing and curbing these diseases. “Next generation sequencing has had a significant impact on diagnostic procedures and is set to gain momentum in the foreseeable future.
AMR analysis suggests that the tremendous potential of novel DNA diagnostic technologies and the probability of them being adopted in personalized medicines has not only reduced the expenditure in diagnostic procedures but has also helped in increasing the efficiency of chronic disease identification. Furthermore, the emergence of personalized medicines and the rising number of initiatives vis–vis product development and clinical trials forkey players has laid the groundwork for DNA diagnostics technologies. Various technologies such as PCR, sequencing technology, microarrayin situ hybridization and mass spectrometry are considered in this report, with special emphasis on key market trends and their growth potential. Given its wide scope of application in almost all activities related to DNA diagnostics, the polymerase chain reaction (PCR) technology holds the largest share of DNA diagnostics market revenue.
DNA Diagnostics Market by Product Type (Instruments, Reagents, Service & Software), Technology (PCR, Microarray, In-situ Hybridization, Sequencing Technology, Mass Spectrometry), Application (Infectious Disease (Hepatitis B Virus, Hepatitis C Virus, HIV, TB, CT/NG, HPV, MRSA), Myogenic Disorder, Prenatal Diagnostics, Pre-implantation Diagnostics) – Global Opportunity Analysis and Industry Forecast, 2013 – 2020
MARKET BY PRODUCT TYPE
Service & Software
MARKET BY TECHNOLOGY
MARKET BY END USERS
Point of Care
Several companies operating in this region are seeking novel technologies to gain traction in the competitive market. Product launch is the key strategy adopted by companies operating in this market. These companies are developing novel products for the treatment of various diseases such as infectious diseases, cancer, prenatal diagnosis, pre-implantation diagnostics and myogenic disorder. Additionally, these companies are also adopting collaboration and acquisition to retain their respective positions and to gain traction in the market. Key companies profiled in the report are Bayer Diagnostic, Sysmex, Roche Diagnostics, Abbott laboratories, Cephide, Gene-probe Inc., Illumina, Inc., Thermo Fisher Scientific, Bio-Rad Laboratories, Johnson and Johnson, and Novartis.
For Purchase Enquiry: https://www.alliedmarketresearch.com/purchase-enquiry/298
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.